Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial

IMPORTANCE: Prior studies have shown that only a small proportion of patients with hormone receptor (HR)–positive metastatic breast cancer (MBC) experience benefit from programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors given as monotherapy. There are data suggesting th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Tolaney, Sara M., Barroso-Sousa, Romualdo, Keenan, Tanya, Li, Tianyu, Trippa, Lorenzo, Vaz-Luis, Ines, Wulf, Gerburg, Spring, Laura, Sinclair, Natalie Faye, Andrews, Chelsea, Pittenger, Jessica, Richardson, Edward T., Dillon, Deborah, Lin, Nancy U., Overmoyer, Beth, Partridge, Ann H., Van Allen, Eliezer, Mittendorf, Elizabeth A., Winer, Eric P., Krop, Ian E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7489368/
https://ncbi.nlm.nih.gov/pubmed/32880602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.3524
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados